Hardin, C. Et Al. 2024. Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).. Special Clinical Science Symposia , (ELECTR NETWORK).

Hardin, C., Gray, C., Novelli, S., Hacibekiroglu, T., Yagci, M., Birhiray, R. E., ... Risal, A.(2024). Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2). . Special Clinical Science Symposia, ELECTR NETWORK

Hardin, Colin Et Al. "Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).," Special Clinical Science Symposia, ELECTR NETWORK, 2024

Hardin, Colin Et Al. "Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).." Special Clinical Science Symposia , ELECTR NETWORK, 2024

Hardin, C. Et Al. (2024) . "Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).." Special Clinical Science Symposia , ELECTR NETWORK.

@conferencepaper{conferencepaper, author={Colin Hardin Et Al. }, title={Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).}, congress name={Special Clinical Science Symposia}, city={}, country={ELECTR NETWORK}, year={2024}}